(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
B12 addresses specific vulnerabilities that come with GLP-1 receptor agonist therapy, from nausea at initiation to nutrient absorption deficits that develop over months of use
People who have diabetes can consume bananas in moderation, preferably if they are small, unripe, and eaten along with protein and healthy fats
The most common reconstitution errors include using the wrong diluent, injecting bacteriostatic water directly onto the powder cake instead of letting it run down the vial wall, shaking the vial vigorously instead of swirling gently, and using the wrong volume of diluent